Reduced expression of NCRs in LDGL patients
Patient no. . | CD16+CD3- cells, % . | NKp46 (BAB281) . | NKp30 (AZ20) . | NKp44 (Z231) . |
|---|---|---|---|---|
| 1 | 82 | 0 | 2 | 0 |
| 2 | 51 | 4 | 2 | 2 |
| 3 | 64 | 26 | 5 | 1 |
| 4 | 75 | 56 | 3 | 0 |
| 5 | 71 | 10 | 1 | 0 |
| 6 | 48 | 10 | 51 | 0 |
| 7 | 40 | 1 | 0 | 0 |
| 8 | 35 | 1 | 0 | 0 |
| 9 | 34 | 11 | 3 | 0 |
| 10 | 62 | 12 | 12 | 5 |
| 11 | 50 | 22 | 2 | 0 |
| 12 | 46 | 3 | 5 | 1 |
| 13 | 70 | 15 | 3 | 0 |
| 14 | 59 | ND | 6 | 5 |
| 15 | 73 | 61 | 2 | 0 |
| 16 | 41 | 1 | 1 | 0 |
| 17 | 71 | 3 | 0 | 0 |
| 18 | 67 | 2 | 1 | 1 |
| CTR1 | 14 | 12 | 12 | 0 |
| CTR2 | 16 | 8 | 6 | 0 |
Patient no. . | CD16+CD3- cells, % . | NKp46 (BAB281) . | NKp30 (AZ20) . | NKp44 (Z231) . |
|---|---|---|---|---|
| 1 | 82 | 0 | 2 | 0 |
| 2 | 51 | 4 | 2 | 2 |
| 3 | 64 | 26 | 5 | 1 |
| 4 | 75 | 56 | 3 | 0 |
| 5 | 71 | 10 | 1 | 0 |
| 6 | 48 | 10 | 51 | 0 |
| 7 | 40 | 1 | 0 | 0 |
| 8 | 35 | 1 | 0 | 0 |
| 9 | 34 | 11 | 3 | 0 |
| 10 | 62 | 12 | 12 | 5 |
| 11 | 50 | 22 | 2 | 0 |
| 12 | 46 | 3 | 5 | 1 |
| 13 | 70 | 15 | 3 | 0 |
| 14 | 59 | ND | 6 | 5 |
| 15 | 73 | 61 | 2 | 0 |
| 16 | 41 | 1 | 1 | 0 |
| 17 | 71 | 3 | 0 | 0 |
| 18 | 67 | 2 | 1 | 1 |
| CTR1 | 14 | 12 | 12 | 0 |
| CTR2 | 16 | 8 | 6 | 0 |
Surface expression of the various receptors was evaluated by FACS analysis using the mAbs indicated in parentheses. Values indicate percentage of positive cells.
ND indicates not done.